2024 Rome, Italy

II-35 Elisa Borella
PKPD modelling of MEN1611 anti-tumor effect in xenograft models to predict efficacy threshold concentrations in HER2-positive advanced or metastatic breast cancer patient population
III-27 Elisa Borella
Vaborem pharmacokinetics and dose rationale in children
III-28 Elisa Borella
Oritavancin pharmacokinetics and dose rationale in children